Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
about
The use of the NIS reporter gene for optimizing oncolytic virotherapyIodine-125 induces apoptosis via regulating p53, microvessel density, and vascular endothelial growth factor in colorectal cancer.Deficiency of caspase 3 in tumor xenograft impairs therapeutic effect of measles virus Edmoston strain.Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy.Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myelomaOncolytic measles virus strains as novel anticancer agents.Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm.Potential and clinical translation of oncolytic measles viruses.Oncolytic viruses-immunotherapeutics on the rise.Oncolytic virotherapy for head and neck cancer: current research and future developments.PET imaging of oncolytic VSV expressing the mutant HSV-1 thymidine kinase transgene in a preclinical HCC rat model.The current status of oncolytic viral therapy for head and neck cancer.Viral Vectors in Gene Therapy.
P2860
Q28083534-8B687861-B9CD-4154-877F-7CD8529C26FFQ35005250-23278F02-F7BB-454F-9A7C-1DDFDFF48D9AQ36140704-01E6BD45-DAF1-422D-8BCD-E38FB8B1D740Q36664219-16DBA6F6-B999-45BC-8A89-95BE5C99CFC9Q37031914-5268FA15-5149-48E1-9041-5BF592455914Q37261017-119E665F-842A-4A91-9F56-349CB0430684Q38264652-EE941AD5-1201-4729-ABC5-06E2884344EDQ38764947-5566A939-E707-49C5-85D7-98D3FEC7A487Q38919107-FC861C5F-2390-4827-A184-C3F78CB797B9Q38924562-FC934CEE-DF83-4BA4-A90D-86E651BA7C11Q39600108-A3C75966-FE49-4DF2-A023-C93EEBD77E91Q52859083-084B2BE4-BC21-4108-A0ED-09D6195DFA60Q55408780-1A9B3DB3-1AF7-437E-9547-30DC6FC0D3BE
P2860
Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Preclinical efficacy of the on ...... aging and radioiodine therapy.
@en
Preclinical efficacy of the on ...... aging and radioiodine therapy.
@nl
type
label
Preclinical efficacy of the on ...... aging and radioiodine therapy.
@en
Preclinical efficacy of the on ...... aging and radioiodine therapy.
@nl
prefLabel
Preclinical efficacy of the on ...... aging and radioiodine therapy.
@en
Preclinical efficacy of the on ...... aging and radioiodine therapy.
@nl
P2093
P2860
P356
P1433
P1476
Preclinical efficacy of the on ...... aging and radioiodine therapy.
@en
P2093
J C Morris
M A Trujillo
N L Eberhardt
S J McDonough
S J Russell
P2860
P2888
P304
P356
10.1038/CGT.2012.47
P577
2012-07-13T00:00:00Z
P5875
P6179
1051572720